New Phase IIIB data shows Novartis Fabhalta improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy
In the Phase IIIB APPULSE-PNH study, oral Fabhalta® (iptacopan) improved the average…
Search
Have an existing account?
Sign In
Tag: anti-c5